US 7968532

I'll search for the specific patent number 7968532 across USPTO and CAFC sources.

The initial searches returned irrelevant matches. Let me search more targeted sources.

Summary — US Patent 7,968,532 B2

Important sourcing note: My web searches for the literal identifier "7968532" surfaced only secondary aggregator pages (Google Patents, Justia, patents-review.com, Patsnap, onscope) plus the patent's own PDF, not an authoritative USPTO PatentCenter or CAFC docket record. I found no CAFC 2026 docket entry naming 7,968,532. Absence of a search hit is not proof that no such litigation exists — I simply cannot confirm or deny a 2026 Federal Circuit docket from the data retrieved. Everything below that is not from search results comes from the authoritative full patent text supplied in my instructions.

Bibliographic data (from authoritative patent text; corroborated by search results)

Assignment history (per the Google Patents record): originally assigned to Ascend Therapeutics, Inc. and Laboratoires Besins International in 2005; reassigned to Laboratoires Besins International (2010) and then Besins Healthcare Luxembourg (2010); renamed Besins Healthcare Luxembourg SARL in 2015. Related family member: EP 1 550 440 A1, "Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia."

Abstract (verbatim)

"The present invention provides methods for treating and preventing gynecomastia by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with gynecomastia, this reduces the effective estrogen-androgen ratio in the breast tissue, thereby reducing ductal proliferation, epithelial and stromal hyperplasia, and pain. In patients at risk for developing gynecomastia, 4-hydroxy tamoxifen's anti-estrogenic effect prevents tissue proliferation and its accompanying pain."

Independent claims — plain-language overview

The patent has 20 claims, but only one independent claim (claim 1). Every other claim depends, directly or indirectly, from claim 1 (or, in a nested chain, from claims 8 or 12). There is no second independent claim.

Claim 1 — A method of treating a male patient suffering from gynecomastia, comprising percutaneously (through the skin) administering an effective amount of 4-hydroxy tamoxifen, where the 4-hydroxy tamoxifen is carried in a vehicle containing isopropyl myristate (a fatty-acid-ester penetration enhancer).

Two limitations do the real limiting work: (a) the patient is a male being treated for gynecomastia (this is a treatment-of-disease claim, not a prophylaxis claim, and the specification's prophylaxis embodiments are not captured by claim 1), and (b) the formulation must include isopropyl myristate.

Dependent claims — grouped by what they add:

• Dosing (claims 2–7): daily per-breast doses of about 0.25–2.0 mg (claim 2), 0.5–1.0 mg (claim 3), and specific values of 0.25, 0.5, 0.75, and 1.0 mg/breast/day (claims 4–7).
• Dosage form (claims 8–11): hydroalcoholic gel (claim 8); gel comprising ethyl alcohol, isopropyl myristate and hydroxypropylcellulose (claim 9); alcoholic solution (claim 10); gel comprising isopropyl myristate, an aqueous vehicle, an alcoholic vehicle and a gelling agent (claim 11).
• Gel composition ranges (claims 12–20): claim 12 sets weight-percentage ranges — 4-hydroxy tamoxifen ~0.01–0.25%, isopropyl myristate ~0.5–2%, absolute alcohol ~65–75%, aqueous vehicle ~20–35%, gelling agent ~0.5–5%. Claims 13–15 then recite enumerated specific values for 4-OHT and isopropyl myristate; claim 16 specifies ethanol/isopropanol at ~62–75% absolute; claim 17 a phosphate-buffered aqueous vehicle at ~25–35%; claim 18 gelling agents selected from polyacrylic acids, hydroxypropylcellulose, ethyl cellulose, hydroxyethyl cellulose, HPMC and CMC; claim 19 a neutralizing agent at ~0.1–5%; and claim 20 packaging in a unit-dose packet or a multi-dose container with a metered pump.

Corroborating detail worth flagging

• The disclosed gel formulations (Table 1) contain 0.02 g or 0.057 g 4-hydroxy tamoxifen per 100 g, 72 g ethanol, 1 g isopropyl myristate, 1.5 g hydroxypropylcellulose, and phosphate buffer q.s. 100 g — i.e., the claim-1 "isopropyl myristate" limitation is squarely supported and is a point of novelty relative to generic 4-OHT topical vehicles.
• The specification's support for the male-gynecomastia indication is largely by extrapolation: the clinical Examples 1–3 were conducted in women (breast-cancer surgery patients and healthy premenopausal women), while the claims are limited to male patients. Example 1 reports 4-OHT concentrating in cytosolic/nuclear breast fractions with minimal metabolism, and Example 3 reports plasma C_max of roughly 17–52 pg/mL across 0.5–2 mg/day dosing.
• Notable prior art cited on the face of the patent includes US 4,919,937 (percutaneous administration of tamoxifen, Mauvais-Jarvis) and EP 0 513 832 (use of dibutyl adipate and isopropyl myristate in topical/transdermal products) — both relevant to the isopropyl myristate limitation.

Stated uncertainties

1. I could not retrieve a primary USPTO PatentCenter or CAFC docket page for this patent; the CAFC 2026 docket search returned no matching record.
2. Litigation involving Besins/Ascend over related 4-hydroxy tamoxifen assets exists in the record (e.g., Atossa Genetics Inc. v. Besins Healthcare Luxembourg SARL, D. Del. 1:16-cv-00045-UNA, settled in 2016), but I found nothing tying 7,968,532 itself to a 2026 appeal.
3. Assignee appears variously as "Besins Healthcare Luxembourg," "Besins Healthcare Luxembourg SARL," and (on Patsnap) "Laboratoires Besins International SAS"; the authoritative patent text and the assignment record support Besins Healthcare Luxembourg SARL as current owner.

I'll search for litigation involving US patent 7968532 across patent litigation databases.

The initial searches returned unrelated patents (different '532 patents). Let me search more specifically for this patent and its owner.

Litigation Search Results: US Patent 7,968,532

⚠️ Important caveat on search reliability

Before listing results, I want to be transparent about a key methodological problem: searches for "7968532" returned mostly unrelated patents that merely end in the digits "532" — e.g., U.S. 7,295,532 (IXI Mobile v. Apple/Samsung), U.S. 4,859,532 (AFG Industries v. Cardinal IG), and a Nox Medical '532 patent. None of these are U.S. 7,968,532. I have not auto-corrected any of those numbers, and I am excluding them from the results below because they are different patents. Per your strict rule, I report only on the literal number 7,968,532 ("Treatment of gynecomastia with 4-hydroxy tamoxifen," priority 2003‑12‑15, assignee Besins Healthcare Luxembourg SARL).

Known litigation specifically asserting US 7,968,532

None confirmed. Based on my searches, I could not identify any patent infringement action (district court, ITC, or CAFC appeal) in which US 7,968,532 was asserted as the patent-in-suit. I could not reach the Unified Patents litigation portal or PACER/CAFC docket queries (tool step limit was hit), so this is a negative finding from limited searching, not a certified all-clear.

Related matter involving the same technology/patent family (but NOT an infringement suit on the '532 patent)

Critical distinction: This case is a license/contract dispute, not a patent infringement action, and the public record I found does not identify US 7,968,532 as an asserted patent. It is relevant only because it concerns the same 4‑hydroxy tamoxifen/Afimoxifene product and the same patent owner (Besins).

Other Besins litigation found (unrelated patents — flagged for completeness, not responsive)

• FTC v. AbbVie Inc., et al. (E.D. Pa., No. 14‑5151; sham-litigation/monopolization over AndroGel). This involves Besins Healthcare, Inc. and AbbVie, but the patent at issue is U.S. 6,503,894 (testosterone gel / isopropyl myristate), not the '532 patent. Oregon AG also settled antitrust allegations against AbbVie/Besins over the same testosterone product.
• Besins oppositions (EPO) against Jina Pharmaceuticals re: endoxifen, and Techsphere — again unrelated to the '532 patent.

Bottom line

I found no confirmed patent infringement litigation asserting US 7,968,532. The only directly adjacent case is the Atossa Genetics v. Besins contract/license suit (D. Del. 1:16‑cv‑00045‑UNA), which settled in 2016 and did not assert the '532 patent. Given that I could not fully query PACER, the CAFC docket, or the Unified Patents litigation portal within these searches, I recommend confirming with a direct USPTO Patent Center "Litigation" tab, Unified Patents Portal, Docket Navigator / RPX Insight, or a PACER district-court search before relying on this as a definitive negative.

If you'd like, I can narrow the next search to specific Besins licensees or the "Afimoxifene" brand and specific district-court dockets.

I'll start by verifying the structured data against live sources, since the canonical block says no AIA trials are on file.

No hits on targeted queries. Let me broaden to litigation/PTAB docket sources and the patent's known family.

Let me check PTAB-specific docket sources and any Unified Patents/defensive-aggregator activity.

PTAB / AIA Trial Analysis — US 7,968,532

Note on sourcing and limitations. The structured "PTAB proceedings on file" block (USPTO Open Data Portal) returns no AIA trial proceedings for US 7,968,532. I ran additional live web searches against PTAB-related dockets and public reporting to look for older or not-yet-indexed filings. Those searches surfaced no IPR, PGR, or CBM naming this patent as the challenged patent, including no defensive-aggregator (Unified Patents–style) filings. I was not able to query PTAB E2E or CourtListener dockets directly with the tools available in this session, so the finding below rests on the ODP block plus affirmative-search negative results, not on a direct E2E docket read. Treat the zero count as high-confidence but not E2E-certified.

---

Proceedings overview

Total AIA trial proceedings on file: 0 — zero active, zero with claims invalidated, zero with claims sustained, zero settled, zero institution denials. The AIA-trial defensive posture for a defendant is therefore "unmapped patent": no claims have been canceled, no claims have been confirmed, no estoppel has attached, and every prior-art ground remains available — but there is also no PTAB record, no panel reasoning, and no institution-stage roadmap to borrow from. A defendant here is a first mover, not a beneficiary of someone else's work.

---

No proceeding to report

There is no {PROCEEDING_NUMBER} to populate. Per the operating instructions ("Do not invent proceeding numbers"), I am reporting the absence rather than constructing a template entry. The sub-fields the task template asks for — judge panel, petition grounds, institution decision, FWD claim-level verdict, settlement, appeal — have no content because no petition was ever filed, or at least none is on file.

Related activity that is not an AIA trial (do not conflate):

• Atossa Genetics, Inc. v. Besins Healthcare Luxembourg SARL, D. Del. Case No. 1:16-cv-00045-UNA (filed 2016-01-28; terminated by settlement 2016-08-04). This was a contract/license dispute over the May 14, 2015 Afimoxifene Topical Gel (AfTG) exclusive license — breach of contract, implied covenant, fraud, negligent misrepresentation, declaratory relief. It was not an infringement action and did not put any claim of US 7,968,532 at issue for validity. The license was terminated and Besins reacquired the AfTG program for a $1,762,931 termination payment. (Atossa press release)
• US 7,968,532 appears as a cited reference in third-party IDS submissions in unrelated proceedings. A P-TACTS petition document contains a form-1449-style listing of "US-7968532-B2, 06-28-2011, LE Nestour et al." (P-TACTS artifact). Being cited as prior art by someone else is not an AIA trial against this patent. It does, however, confirm the disclosure is being used as art against others — worth knowing if you are defending on the other side of that equation.

---

Strategic summary

Claim status: everything is UNTESTED. No claim of US 7,968,532 has been canceled, narrowed, or confirmed by the PTAB. Claims 1–20 — including independent claim 1 (a method of treating a male patient suffering from gynecomastia by percutaneously administering an effective amount of 4-hydroxy tamoxifen, wherein the 4-hydroxy tamoxifen is in a vehicle comprising isopropyl myristate) and the hydroalcoholic-gel-dependent claims 8–20 — all stand exactly as issued on 2011-06-28. This is the opposite of the "claims 1–5 are canceled" posture the task template contemplates: any claim the patent owner asserts is live and unrebutted by any PTAB record.

Estoppel landscape: none, and that cuts your way. Because no IPR was instituted, § 315(e)(2) estoppel never attached to anyone. There is no petitioner and no privy barred from raising anything. Every § 102 and § 103 ground — including grounds that a prior petitioner could have raised — remains fully available to a defendant in district court or in a first-filed IPR. The entire pre-2004 4-hydroxy tamoxifen literature is fair game, and it is substantial: the patent's own specification concedes Kuttenn et al. (1985), Mauvais-Jarvis et al. (1986), and Pujol et al. (1995) describe percutaneous 4-OHT in humans with breast-tissue concentration data — i.e., the patent owner's own cited art establishes percutaneous 4-OHT delivery pharmacology pre-dating the 2003-12-15 priority date. The likely battleground is not whether percutaneous 4-OHT reaches breast tissue, but whether applying that known delivery route to the known indication of gynecomastia (cf. Gruntmanis & Braunstein 2001 on tamoxifen for gynecomastia, cited in the specification) was nonobvious.

Procedural vehicle check. The application was filed 2004-12-13 with a 2003-12-15 priority date, so this is a pre-AIA patent. That matters:

• PGR is unavailable — post-grant review only reaches patents with an effective filing date on or after 2013-03-16.
• CBM is unavailable — the claims are directed to a method of medical treatment, not a "financial product or service."
• IPR is the only AIA trial vehicle, and it must be filed within one year of service of a complaint alleging infringement on you (§ 315(b)).
• Non-AIA alternatives (ex parte reexam, or In re citation of prior art) remain outside the PTAB and outside the task's scope.

Pattern signals. No repeat-petitioner pattern is possible — there is no petitioner at all. The patent owner, Besins Healthcare Luxembourg SARL, is a privately held specialty pharma company, not a non-practicing entity; it has actively commercialized (Afimoxifene Topical Gel / 4-OHT gel) and licenses this family (the 2015 Atossa license covered "10 patent families"). That cuts both ways: a commercializing owner has more incentive and resources to defend, but also tends to attract Hatch-Waxman/ANDA challengers — and the absence of a single IPR over a ~13-year post-grant life is itself a signal that either (a) the patent has never been asserted against a well-funded generics defendant in a way that triggered an IPR, or (b) prospective defendants have chosen district-court invalidity, design-around, or the family's other members instead. The sibling patents in this family — e.g., US 7,507,769, US 7,485,623, US 7,704,516, US 7,786,172, US 7,767,717 — would be the natural IPR targets if a challenger wanted to clear the portfolio; I did not confirm whether any of those were challenged, and I am not asserting they were. That is a gap you should close before relying on this memo.

Term position. The ODP/Google Patents record lists an adjusted expiration of 2027-03-07 (with a 2004-12-13 filing date and 2003-12-15 priority). Roughly 17 months of enforceable life remain as of today (2026-09-30), subject to maintenance-fee status. Confirm the fee record before investing in a validity fight — the cost/benefit of an IPR changes materially if the patent lapses sooner.

---

Recommended next steps

1. If you are a defendant facing assertion: the patent has not been narrowed by any IPR, so there is no FWD to link to and no canceled claim to cite. Do not represent that any claim is dead. Your two realistic paths are (a) a district-court invalidity/§ 112 case built on the pre-2003 percutaneous 4-OHT literature the specification itself cites (Mauvais-Jarvis 1986; Pujol 1995; Kuttenn 1985) combined with Gruntmanis & Braunstein 2001 on tamoxifen for gynecomastia, or (b) a first-filed IPR — accepting that you carry full § 315(e) estoppel risk with no predecessor work product to build on.
2. Watch the § 315(b) clock. If you have been served with a complaint alleging infringement of US 7,968,532, your one-year IPR window is running. Calendar it. Note also that a statutory FWD deadline runs one year from institution (§ 316(a)(11)), and the institution decision itself is due within six months of the petition's filing date.
3. Do not treat "no PTAB activity" as a clean bill of health. It is a signal about litigation history, not about patent strength. The claims are untested, which means both that your invalidity grounds are wide open and that the patent owner has no adverse PTAB precedent to overcome.
4. Verify directly before relying on this. PTAB E2E (https://ptacts.uspto.gov) proceeding search by patent number, and CourtListener's docket search (https://www.courtlistener.com) for "7,968,532," would resolve the residual uncertainty from my limited search access. Also check the sibling family members listed above for challenges that could create collateral estoppel or issue-preclusion spillover arguments against overlapping claim scope.

I'll start by gathering what's verifiable from the authoritative patent text and cross-checking with public sources.

Let me cross-check litigation history and assignment data sources.

Ownership Reconstruction — US 7968532 ("Treatment of gynecomastia with 4-hydroxy tamoxifen")

Scope caveat up front (read this before the sections): I could not load assignmentcenter.uspto.gov or assignment.uspto.gov directly from this session, and no secondary index I could reach exposes the Assignment Center reel/frame and correspondent of record fields for this patent. The assignment chain below is reconstructed from the Google Patents legal-events feed embedded in the authoritative patent record you supplied, which reproduces USPTO assignment events (type, assignor, assignee, recordation date, and — for one entry — the reel/frame). Only one reel/frame is recoverable from the sources I reached: Reel 016419 / Frame 0157. Everything else is stated without a reel/frame because I did not obtain one; I have not inferred or invented reel numbers. Correspondents of record were not retrievable for any link, and that gap is flagged as a finding below.

---

Inventors

Pattern notes.

• This is not an "all inventors departed within 12 months of filing" pattern. Both inventors assigned to their respective employers on the same day (2005-04-01), roughly 16 months after the 2003-12-15 priority date and about 3.5 months after the 2004-12-13 US filing — i.e., routine confirmatory employment assignments, the standard hygiene step before an application publishes (US20050158388A1 published 2005-07-21). Nothing here precedes a portfolio fire-sale.
• The bipartite split (one inventor → Besins, one inventor → Ascend) is the material fact: it reflects the underlying deal structure in which Ascend, a US specialty-pharma startup, in-licensed Besins' "Enhanced Hydroalcoholic Gel" (EHG) transdermal platform and took North American development rights. Ownership of the resulting IP was co-tenancy between a French/Belgian pharma group and a US VC-backed licensee.
• Data inconsistency to flag: Google Patents renders the 2004-12-13 filing event as "Application filed by Besins Healthcare Luxembourg SARL." That is an anachronism — that entity did not exist under that name in 2004. The published application and its EP counterpart (EP 1694319 A1, per PubChem/Espacenet) list both "BESINS INT LAB (FR)" and "ASCEND THERAPEUTICS INC (US)" as applicants. Treat the Google "filed by" label as a retro-applied current-assignee field, not historical fact.

---

Original assignee

Two co-assignees of record at issuance:

1) Ascend Therapeutics, Inc. — Herndon, Virginia, US. Clinical-stage specialty pharmaceutical company founded 2002 by Jay Bua, a 1988–2002 veteran of Laboratoire Besins who had nursed AndroGel through commercialization. Its business was transdermal re-formulation of known drugs using Besins' EHG gel; its lead asset was TamoGel (afimoxifene = 4-hydroxytamoxifen gel), in Phase II for cyclic mastalgia with stated development interest in gynecomastia and breast-cancer chemoprevention (contemporaneous trade coverage: "Topical Tamoxifen Benefits Cyclic Mastalgia," San Antonio Breast Cancer Symposium report; Ascend's own reprint of a Washington Business Journal-style profile, ascendtherapeutics.com). Financing initially from Besins insiders, ~$19M raised by 2004. Status: Ascend assigned its entire interest to Laboratoires Besins International on/around 2010-08-31 (record date). I do not have a confident record of Ascend's later corporate status (operating / wound down / dissolved) — I am explicitly declining to guess.

2) Laboratoires Besins International — operating hormone-therapeutics pharma group (now branded Besins Healthcare). Products include AndroGel (testosterone gel, partnered to Solvay/AbbVie), Utrogestan/Prometrium (progesterone), and estradiol gels. Status: operating. Note that progestogen-containing products are listed as jointly owned with Unimed Pharmaceuticals, LLC / AbbVie in later national registers (e.g., Latvia Patent Office register, EP 1937276, address-change entry dated 2024-08-15).

Does the current owner ship a product embodying the claims? Not verifiable as yes. Claim 1 is specific: percutaneous 4-hydroxy tamoxifen in a vehicle comprising isopropyl myristate, for a male gynecomastia patient. Afimoxifene/TamoGel is characterized in the clinical and DrugBank literature as an investigational product ("under investigation... developed by Ascend Therapeutics"), and the patent's own data come from breast-cancer-surgery and healthy-volunteer PK studies, not a marketed gynecomastia product. I found no evidence of an FDA-approved product practicing claim 1. I am not asserting there is none — only that I could not confirm one.

Portfolio context (relevant to the NPE analysis): this patent sits in a Besins/Ascend 4-OHT family that surfaced in the same ownership chain — e.g., US 7,704,516 (percutaneous 4-OHT composition), US 7,485,623 (breast density), US 7,785,172 (mastalgia), US 7,507,769 (benign breast disease). All were consolidated into Besins, not scattered to unrelated holders.

---

Assignment timeline

Important limitation, stated once and applying to every row: the recordation/event dates below are those exposed by the Google Patents legal-events feed; execution dates are not exposed in that source and I have not supplied them. Reel/frame is recorded only where affirmatively available (one entry). Correspondent of record is unavailable for every entry — see signal 3 below for why that matters.

2004-12-13 — US application 11/009,390 filed. Not an assignment. Filed by Ascend Therapeutics, Inc. and Laboratoires Besins International as co-applicants (per published US20050158388A1 / EP 1694319 A1). Google's "filed by Besins Healthcare Luxembourg SARL" label is retro-applied and should be disregarded.

• Context: initial filing of the co-owned asset.

2005-04-01 — Reel/frame not retrievable

• Conveyance: Assignment of assignors' interest (executed assignment)
• Assignor: Andrew R. Palumbo
• Assignee: Ascend Therapeutics, Inc.
• Correspondent: not retrievable from accessible sources (see signal 3)
• Context: confirmatory employment assignment; inventor to his employer.

2005-04-01 — Reel 016419 / Frame 0157 (inferred from the corrective assignment's own citation; see the 2005-09-27 entry)

• Conveyance: Assignment of assignors' interest (executed assignment)
• Assignor: Elisabeth Le Nestour
• Assignee: as originally recorded, a mis-spelled "LABORATORIES BESINS INTERNATIONAL"
• Correspondent: not retrievable from accessible sources
• Context: confirmatory employment assignment; inventor to her employer. The mis-spelling of the assignee's legal name is what triggered the corrective filing four months later.

2005-09-27 — recorded; cites prior record at Reel 016419 / Frame 0157

• Conveyance: Corrective assignment — the record states it corrects the assignment previously recorded at Reel 016419, Frame 0157 to correct assignee name
• Assignor: Elisabeth Le Nestour
• Assignee: LABORATOIRES BESINS INTERNATIONAL (corrected spelling)
• Correspondent: not retrievable from accessible sources
• Context: correction-of-record only — no change in beneficial ownership. This is an administrative fix, not a transfer.

2010-08-31 — Reel/frame not retrievable

• Conveyance: Assignment of assignors' interest
• Assignor: Ascend Therapeutics, Inc.
• Assignee: Laboratoires Besins International
• Correspondent: not retrievable from accessible sources
• Context: consolidation of co-ownership — the US licensee/developer of the 4-OHT gel assigned its entire undivided interest to the Besins parent, ending co-tenancy. This is the substantive event that put 100% of the patent in the Besins group.

2010-08-31 — Reel/frame not retrievable

• Conveyance: Assignment of assignors' interest
• Assignor: Laboratoires Besins International
• Assignee: Besins Healthcare Luxembourg (no SARL suffix yet)
• Correspondent: not retrievable from accessible sources
• Context: intra-group transfer of the asset into the group's Luxembourg IP-holding company. Note the same-day sequencing with the Ascend assignment — this is a clean-up/step-transaction structure, not an arm's-length sale.

2011-06-28 — Patent issues as US 7968532 B2. Not an assignment. (Adjusted expiration shown as 2027-03-07; status Active.)

2015-02-04 — Reel/frame not retrievable

• Conveyance: Change of Name
• Assignor: Besins Healthcare Luxembourg
• Assignee: Besins Healthcare Luxembourg SARL
• Correspondent: not retrievable
• Context: change of name only — no change in ownership or beneficial interest.

2015-02-06 — Reel/frame not retrievable

• Conveyance: Correction of Address
• Assignor: Besins Healthcare Luxembourg
• Assignee: Besins Healthcare Luxembourg SARL
• Correspondent: not retrievable
• Context: address correction only.

2015-07-29 — Reel/frame not retrievable

• Conveyance: Change of Address
• Assignor: Besins Healthcare Luxembourg SARL
• Assignee: Besins Healthcare Luxembourg SARL
• Correspondent: not retrievable
• Context: address change only — consistent with the group's two Luxembourg addresses seen elsewhere in the public record (67 Boulevard Grande-Duchesse Charlotte, L-1331; and 2-8 rue Julien Vesque, L-2668), e.g., the Latvian register's address-change entries for EP 1937276.

Summary of the chain: Palumbo → Ascend; Le Nestour → Laboratoires Besins International (with a name correction); Ascend → Laboratoires Besins International (2010); Laboratoires Besins International → Besins Healthcare Luxembourg (2010); then pure name/address housekeeping (2015). Five substantive-or-corrective records and three administrative records; a single beneficial owner since 2010.

---

Timeline diagram

timeline
    title Ownership of US 7968532
    2003 : Priority filing by Besins and Ascend
    2004 : US application filed by both owners
    2005 : Palumbo assigns to Ascend Therapeutics
         : Le Nestour assigns to Besins
         : Corrective assignment fixes name
    2010 : Ascend assigns its interest to Besins
         : Besins Intl assigns to Luxembourg
    2011 : Patent issues as US 7968532
    2015 : Change of name to Luxembourg SARL
         : Address corrections recorded

---

NPE / troll-pattern signals

1. Shell-entity transfer — not present.
The patent did move into an entity named "Besins Healthcare Luxembourg SARL," which is a Luxembourg-domiciled holding company, so the location-plus-holding-form deserves a look rather than a shrug. But the identifying tells are absent: the name carries no "IP / Patents / Licensing / Holdings / Ventures" suffix; the entity is not single-purpose — IP owner profiles show it holding ~92–105 IP rights across patents and trademarks (first patent 2000, last patent 2020, last trademark 2023) and it files its own new applications rather than only acquiring; and it is the IP vehicle of an operating hormone-therapeutics group with marketed products and clinical activity. Evidence: Onscope/IPqwery "Besins Healthcare Luxembourg SARL" owner profile (last patent 2020 "Spray-dried pharmaceutical compositions"; inventions 2016 "4-hydroxy tamoxifen gel formulations," 2019 "Transdermal pharmaceutical compositions comprising a SERM"). A Luxembourg IP holdco is a tax-structuring fact, not, on this record, an NPE fact. No registered-agent-service address or single-member-LLC indicium appears.

2. Known asserter in the chain — not present.
The three entities in the chain are Ascend Therapeutics, Inc., Laboratoires Besins International, and Besins Healthcare Luxembourg SARL. None appears on the enumerated lists (Acacia, Marathon, IV, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). Ascend was a VC-financed clinical-stage drug developer in-licensing a platform, not a licensing-only assertion vehicle.

3. Repeat correspondent across the chain — unclear / not determinable (and this is a genuine gap, not a "no").
This is the one signal I was asked to prioritize and could not execute: the Assignment Center's correspondent-of-record field was not retrievable for any of the eight recorded entries, so the distinctive test (same attorney recurring across shell entities) cannot be run. I will not manufacture a correspondent. One discrete lead exists and I flag it as a lead, not as evidence for this chain: the USPTO trademark record for BESINS (Reg. No. 4095110, Ser. No. 79093842, filed by Besins Healthcare Luxembourg S.A.R.L.) lists attorney "BESCH, JAY C" as the prosecuting attorney — a plausible Besins-group outside counsel, but I have no evidence linking that attorney to the assignment recordings on US 7968532. To close signal 3, pull the correspondent field for Reels recorded 2005-04-01, 2005-09-27, and 2010-08-31 in Assignment Center.

4. Cascading transfers — not present.
There is no chain of LLCs flipping the asset in under 24 months. The two substantive transfers bracket a five-year gap (2005 → 2010), and the 2010 pair is a same-day two-step consolidation into one corporate family, not a cascade. The 2015 entries are change-of-name and address only. There are no shared-principal intermediary entities.

5. Pre-litigation transfer — not present.
I found no infringement litigation naming US 7968532 in the searches I ran. With no first suit to anchor against, the six-month look-back is inapplicable. The last substantive transfer (2010) predates issuance (2011) by roughly nine months, which is the opposite of a pre-litigation arrangement — it preceded the patent even existing.

6. Bankruptcy fire-sale — not present (no evidence surfaced).
No Chapter 7/11 record for Ascend Therapeutics or Laboratoires Besins International appeared in my searches. Caveat: Ascend's 2010 assignment of its entire interest back to the Besins parent is consistent with a wind-down or loss of independence, and I could not confirm Ascend's corporate status. This does not rise to a bankruptcy finding; it is an open item.

7. Privateering — not present.
The direction of travel here is the inverse of privateering. Privateering runs operating company → assertion vehicle to sue competitors. What happened is assertion-capable vehicle / co-owner (Ascend) → operating parent (Besins), i.e., the operating pharma group pulled the IP in-house. No SEC-filed or Patent Progress/EFF-surfaced privateering arrangement is implicated.

8. Defensive aggregator — not present.
The chain does not terminate at RPX, AST, LOT Network, Unified Patents, or OIN. It terminates at Besins Healthcare Luxembourg SARL, a practicing pharma group's IP holder. The patent is therefore not "neutralized" by an aggregator — it remains a live, assertable asset (status Active; adjusted expiration 2027-03-07) held by a company with commercial interests.

---

Verdict

Insufficient data.

Justification (2–3 sentences, per the stated definitions): The recorded chain is unusually clean and points away from every NPE signal: inventor assignments on 2005-04-01 to the two real employers (Palumbo → Ascend; Le Nestour → Labortatoires Besins International, corrected at Reel 016419/Frame 0157 on 2005-09-27), a 2010-08-31 consolidation in which Ascend assigned its entire undivided interest to Laboratoires Besins International, and a same-day intra-group transfer to Besins Healthcare Luxembourg that was followed only by 2015 change-of-name/address housekeeping — i.e., a single operating pharma family has owned 100% of the asset since 2010, with no intervening LLCs, no <24-month cascade, and no identified litigation. I nonetheless decline to select "Operating-company assertion" (which under the rubric requires the current assignee to be suing competitors — it is not) or "Defensive / non-asserting" (which requires termination at a defensive aggregator — it did not), and I cannot select an NPE verdict (zero supporting signals). The honest characterization is that the ownership evidence is exculpatory but the Assignment Center metadata the rubric requires — reel/frame per link and, critically, the correspondent of record — could not be retrieved in this session, so signal 3 remains untested.

Recommended verification, in priority order:

1. Search US 7968532 in the Assignment Center and record the correspondent of record for the 2005-04-01, 2005-09-27 (Reel 016419/0157), and 2010-08-31 recordings — this is the single highest-value missing datum: https://assignmentcenter.uspto.gov/ or https://assignment.uspto.gov/patent/index.html.
2. Confirm whether Ascend Therapeutics, Inc. remains an operating entity or was wound down after the 2010 interest assignment (state corporate registry for Virginia / Delaware; any assignment-out-of-bankruptcy record).
3. Confirm whether any assertion has ever involved US 7968532 or its family siblings (US 7,704,516; 7,485,623; 7,785,172; 7,507,769) via PACER/Docket Navigator and the RPX/Unified high-frequency-plaintiff directories.

Nothing in this report should be read as a legal conclusion on ownership, validity, or enforceability. All reel/frame references other than Reel 016419/Frame 0157 are unavailable from the sources I reached and are marked as such rather than estimated.

I'll verify key prior-art references from the patent's cited list, grounding each in current search results before mapping them to claims.

Let me verify several more cited references relevant to the claims' formulation and antiestrogen elements.

Prior-Art Analysis — US 7,968,532 B2 ("Treatment of gynecomastia with 4-hydroxy tamoxifen")

Sourcing and scope note

I worked from the authoritative full patent text (Google Patents record for US 7,968,532 B2, which reproduces the complete "Citing/Cited" reference lists) that was supplied in my instructions, corroborated by targeted web verification of the key references. Building on the two earlier sections, I do not repeat the bibliographic summary or the litigation findings; where they matter they are cross-referenced. No similar-number references were substituted — everything below is tied to the literal identifier 7,968,532 and its listed citations. As flagged previously, I could not reach a primary USPTO PatentCenter page or CAFC docket, so the reference list below is taken from the patent's own face and full-text record, not an examiner's PTO-892 image.

---

1. The governing law and the critical trigger

US 7,968,532 was filed December 13, 2004, claiming priority to December 15, 2003. Because its effective filing date precedes March 16, 2013, pre-AIA 35 U.S.C. § 102 governs. The relevant prior-art windows are:

⚠ The dispositive structural point for § 102 anticipation

All 20 claims depend, directly or indirectly, from claim 1 (see the earlier summary). Claim 1 requires three independent limitations to be met in a single reference:

1. a method of treating a male patient suffering from gynecomastia;
2. percutaneous administration of an effective amount of 4-hydroxy tamoxifen (4-OHT); and
3. the 4-OHT in a vehicle comprising isopropyl myristate (IPM).

No cited reference discloses all three. Therefore, no cited reference fully anticipates claim 1 or any claim that depends from it, because every dependent claim imports claim 1's male-gynecomastia, percutaneous-4-OHT, and IPM elements. The cited art is therefore best characterized as § 103 obviousness art, not as § 102 anticipatory art. The mapping below identifies, honestly, (i) which references come closest, and (ii) which claim limitation(s) each reference would supply if combined.

---

2. Full table of the 42 cited patent references

Dates are priority date → publication/issue date, as listed on the patent. "§ 102 hook" gives the subsection under which the reference would most aptly qualify. Claim references are to the '532 claims.

---

3. Detailed § 102 mapping of the most relevant references

TIER 1 — Closest to claim 1 (but none complete)

US 4,919,937 A — Mauvais-Jarvis & Kuttenn, "Percutaneous administration of tamoxifen"

• Dates: FR priority 1984-01-20; PCT filed 1984-12-21; U.S. national stage 1985-09-13; issued 1990-04-24. Squarely § 102(b).
• Disclosure (verified): Claims an anti-estrogen drug whose active product is 1-(p-dimethylaminoethoxyphenyl)-trans-1-(p-hydroxyphenyl)-2-phenylbut-1-ene — i.e., 4-hydroxy tamoxifen — presented as an aqueous/alcoholic gel that is percutaneously administrable, optionally with progesterone, "for the treatment of breast affections, particularly benign [and] cancerous affections of the breast." The specification expressly notes that tamoxifen itself cannot be activated percutaneously to 4-OHT because breast tissue lacks the hepatic enzymes.
• § 102 analysis: This is the single most damaging reference for the route + active-ingredient + dosage-form elements. It discloses limitations 2 and (archetypally) the hydroalcoholic gel of claims 8, 10, 11, 12. It supplies no isopropyl myristate (its gel uses Carbopol®/carbomer, ethyl alcohol, water) and no gynecomastia/male indication. It therefore cannot anticipate claim 1; it is core § 103 art.

US 5,904,930 A / WO 95/24187 A1 — Hexal AG (Fischer, Klokkers, Sendl-Lang)

• Dates: DE priority 1994-03-08; WO published 1995-09-14; US issued 1999-05-18. § 102(b).
• Disclosure (verified): Claim 1 recites a transdermal patch comprising "3-hydroxytamoxifen and/or 4-hydroxytamoxifen" in the form of a solution in an alcohol, with vitamin E, a reservoir, backing foil, microporous membrane, and adhesive layer. Explicitly discusses 4-OHT's lipophilicity and need for absorption promoters.
• § 102 analysis: Directly supplies the percutaneous 4-OHT element for the patch embodiments and claim 10 (alcoholic solution). Note that the '532 specification's two patch-described alternatives ((a)–(e) cavity patch; open-pored/closed-pore foam reservoir) track the Hexal disclosure closely — a point of § 103 overlap. Missing IPM and gynecomastia.

US 7,704,516 B2 / US 2005/0031695 A1 — Besins/Ascend, "Percutaneous composition comprising 4-hydroxy tamoxifen"

• Dates: priority 2003-04-01 (pre-dates the '532 priority); US issued 2010-04-27. § 102(e) as to the granted patent; but commonly owned / same family (Besins → Ascend), so disqualified for § 103 by pre-AIA § 103(c).
• Disclosure (verified): Hydroalcoholic 4-OHT gel containing isopropyl myristate, a gelling agent and an aqueous/alcoholic vehicle, with dose ranges (e.g., the family's ES 2 483 896 T3 claims recite 4-OHT + isopropyl myristate + aqueous vehicle + alcoholic vehicle + gelling agent at 0.25–2.0 mg/breast/day).
• § 102 analysis: This is the only reference that recites 4-OHT + IPM together → it supplies the claim-1 IPM limitation and the claim-11/12 composition. It does not disclose male gynecomastia, and it is the applicant's own family, so it cannot anticipate but confirms the formulation was known within the portfolio.

US 6,503,894 B1 — Unimed Pharmaceuticals (AndroGel), "Pharmaceutical composition and method for treating hypogonadism"

• Dates: priority 2000-08-30; issued 2003-01-07. § 102(b).
• Disclosure (verified): 1% testosterone hydroalcoholic gel whose vehicle contains isopropyl myristate with ethanol and a carbomer thickener, dispensed by a metered pump.
• § 102 analysis: Supplies the IPM-in-hydroalcoholic-gel element and the metered-pump packaging element (claim 20), but a different active. Key § 103 art for claims 8, 11, 12, 15, 20. (It is the same AndroGel IPM platform litigated in the FTC/Oregon AG matters over US 6,503,894 referenced in the earlier litigation section — not the '532 patent.)

EP 0 513 832 A1 / US 5,326,566 — Bristol-Myers Squibb (Parab)

• Dates: priority 1991-05-17; EP published 1992-11-19 (B1 2000-07-26); US issued 1994-07-05. § 102(b).
• Disclosure (verified): Use of dibutyl adipate and/or isopropyl myristate as skin-penetration enhancers in topical/transdermal compositions; claims recite IPM at, e.g., 1–30 wt%.
• § 102 analysis: The clearest IPM-as-enhancer teaching → supplies the IPM element of claim 1 and the weight ranges of claims 12, 15. No 4-OHT, no gynecomastia.

TIER 2 — 4-OHT compound/composition references (active-ingredient and solubility art)

TIER 3 — Antiestrogen/indication-adjacent art (the "gynecomastia" and "estrogen-antagonist" elements)

• EP 0 792 640 A2 / US 2004/0009994 A1 (Pfizer) — 1996-02-28 priority. (E)-1-(4'-(2-alkylaminoethoxy)phenyl)-1-(3'-hydroxyphenyl)-2-phenylbut-1-enes and their use as estrogen antagonists for "inhibiting pathological conditions." § 102(b)/(e) art for the antiestrogen-treatment concept; different hydroxyphenyl regiochemistry, so not an anticipation of a 4-OHT-specific claim.
• US 2002/0115676 A1 (Maclean) — 2000-11-30 priority, § 102(e). "Therapy for andropause using estrogen agonists/antagonists and testosterone." This is the most likely cited reference to supply the gynecomastia link (testosterone/andropause therapy is a classic gynecomastia context), but it does not disclose 4-OHT or IPM.
• US 2001/0041718 A1 (Thompson) — 2000-01-12, § 102(e). Compositions/methods for conditions "responsive to estrogen" — indication-adjacent.
• US 2003/0065017 A1 (Ke); US 2003/0175329 A1 (Cellegy, semisolid topical hormones); US 2005/... (Masini-Eteve DHT gel, 2001-11-07); US 2003/0150876 A1 (SeaquistPerfect pump dispenser, 2002-02-12); US 2004/0086552 A1 (Klokkers, 2000-07-12) — collectively supply the topical-gel formulation, hydroalcoholic-vehicle, and metered-dispenser elements (§ 102(e)). Claim-20 mapping is specifically supported by the SeaquistPerfect dispenser reference.

TIER 4 — Background/peripheral (included for completeness; no meaningful § 102 mapping)

DE 3238984 A1 (progesterone); US 5,045,553 (Fujisawa permeation promoter); DE 3836862 A1 (Schering transdermal steroids); US 5,613,958 (PP Holdings); US 5,820,877 (Hisamitsu patch); US 5,720,963 (Mary Kay); WO 97/36570 & US 5,945,109 (S.W. Patentverwertungs cosmetics); US 6,013,270 (P&G skin-care kit); WO 01/43775 (Dermatrends enhancers). These teach percutaneous-delivery or cosmetic background only and do not approach claim 1.

TIER 5 — Not prior art (listed on the face for family/related reasons)

EP 1 579 857 A1, US 7,507,769 B2, EP 1 579 856 A1, US 2005/0208139 A1, US 2005/0209340 A1, US 2006/0105041 A1, and US 7,767,147 B2 all carry 2004 priority dates (March/October 2004) — after the '532 Dec 15, 2003 priority date. They cannot be § 102 or § 103 prior art against claim 1. (US 7,767,147 is also technologically unrelated — a Hitachi liquid-transport substrate.)

---

4. Bottom line on § 102

The nearest thing to an anticipation theory would be a single reference that disclosed (a) percutaneous 4-OHT and (b) an IPM vehicle and (c) the male-gynecomastia indication. The record contains no such reference. The strongest § 102 attack would look to US 4,919,937 (percutaneous 4-OHT gel) — but it fails the IPM and gynecomastia limitations, so it is an obviousness reference, not an anticipation reference.

The genuine defensive significance of the cited art is § 103-based: a prima facie obviousness case could be assembled by combining (i) US 4,919,937 or US 5,904,930 (percutaneous 4-OHT) with (ii) EP 0 513 832 or US 6,503,894 (IPM-containing topical/hydroalcoholic vehicle) and a gynecomastia/antiestrogen teaching (e.g., US 2002/0115676 or the gynecomastia NPL cited in the specification — Mathur & Braunstein 1997; Gruntmanis & Braunstein 2001; Lazala & Saenger 2002). The patent's principal non-obviousness arguments necessarily rest on (a) the surprise that per-cutaneously delivered 4-OHT treats/prevenes male gynecomastia with low systemic exposure, and (b) the specific IPM-hydroalcoholic-gel formulation — neither of which appears in a single cited reference.

Confidence and caveats

• The reference list, dates, and titles are taken from the authoritative full patent text and are high confidence; where I quoted disclosure (US 4,919,937, US 5,904,930, EP 0 513 832 / US 5,326,566, WO 99/33451, US 7,704,516) I verified against primary patent documents recovered in search.
• Medium confidence on US 6,632,841 (Orion) and the Pfizer references' precise disclosures; I did not retrieve their full texts, so their § 102 characterization is based on titles/abstracts.
• Low confidence / flag: I could not confirm whether any cited reference expressly names gynecomastia in a male context. The gynecomastia-specific element appears to come from the specification's non-patent citations (e.g., Gruntmanis & Braunstein 2001 on tamoxifen for gynecomastia), not from any of the 42 patent references. If the task requires a definitive answer on whether, e.g., the Pfizer or Thompson references mention gynecomastia, their full texts should be pulled.
• Because all claims depend from claim 1, my "no full § 102 anticipation" conclusion holds even if a Tier 2/3 reference mentions gynecomastia — it would still lack the IPM and/or percutaneous-4-OHT limitations.

I'll ground my analysis in the prior-art references cited in the patent's Prior Art section and the non-patent literature it relies on. Let me verify characterizations of the key references before building the § 103 analysis.

I now have strong grounding. Let me verify three more references that are central to the claim limitations (the gynecomastia indication, the 4-OHT topical composition, and the dosing study).

Obviousness Analysis — U.S. Patent 7,968,532 B2 under 35 U.S.C. § 103

Analyst note / scope. This is a technical obviousness assessment, not a legal opinion. It is built from (a) the authoritative full patent text supplied, (b) the prior-art references cited on the face of the patent and in its "Prior Art" section, and (c) targeted web verification of those references. Where I could not retrieve a full reference text, I say so. The priority date is December 15, 2003; all references below predate it.

---

I. Legal framework

A claim is obvious where "the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art." 35 U.S.C. § 103(a). The controlling framework is Graham v. John Deere Co., 383 U.S. 1 (1966) (scope/content of prior art; differences; PHOSITA level; secondary considerations), as refined by KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007).

KSR is particularly important here because the claimed invention is a combination of known elements — a known drug, a known route of administration, a known excipient, and a known indication. Under KSR, a combination is obvious where (i) the elements were known in the art, (ii) there was a known problem for which there was an apparent (predictable) solution, and (iii) a PHOSITA would have had a reasonable expectation of success. KSR also sanctions the rationales catalogued in MPEP § 2143: combining prior-art elements per known methods to yield predictable results; simple substitution of one known element for another; use of a known technique to improve a similar device in the same way; and "obvious to try" where the number of identified, predictable solutions is finite.

The key point for this patent: the specification itself supplies much of the motivation to combine. It concedes that tamoxifen is the recognized gynecomastia therapy (citing Gruntmanis & Braunstein 2001) and that tamoxifen's drawbacks are its systemic effects arising from first-pass hepatic metabolism — the very problem topical 4-OHT was known to solve.

---

II. Level of ordinary skill in the art (PHOSITA)

A PHOSITA here would be a physician-scientist in endocrinology/oncology or a pharmaceutical formulation scientist, with several years of experience in topical/transdermal drug delivery — or, realistically, a team spanning both. Such a person would know: (1) the pharmacology of tamoxifen and its active metabolite 4-hydroxy tamoxifen (4-OHT); (2) that gynecomastia is an estrogen-driven benign proliferation of male breast tissue; (3) the fundamentals of percutaneous absorption and the standard catalogue of penetration enhancers (including isopropyl myristate); and (4) standard hydroalcoholic gel excipient systems.

---

III. What claim 1 actually requires

Claim 1 (the sole independent claim) requires four elements:

1. A method of treating (not preventing) a male patient;
2. Who is suffering from gynecomastia;
3. By percutaneous administration of an effective amount of 4-hydroxy tamoxifen;
4. Wherein the 4-OHT is in a vehicle comprising isopropyl myristate (IPM).

Claims 2–7 add per-breast/day doses; claims 8–11 specify dosage form (hydroalcoholic gel, alcoholic solution, and gel components); claims 12–20 recite gel weight-percentage ranges and species.

Each of the four claim-1 elements is separately disclosed or rendered obvious by the prior art, and the combination is a textbook KSR case.

---

IV. The key prior art (all pre-2003-12-15)

Note on the patent family's own later filings: the "Cited By" list includes US 2006/0105041 ("4-Hydroxy tamoxifen gel formulations") and the "Chemically stable compositions" family — these are later Besins filings, not prior art, and are noted only for context.

---

V. Obviousness grounds

Ground 1 (primary) — US 4,919,937 + Gruntmanis & Braunstein 2001 + EP 0 513 832

This combination renders claim 1 obvious.

(a) US 4,919,937 supplies elements 3 and much of 1–2. It discloses a percutaneous hydroalcoholic gel of 4-OHT, teaches that it concentrates in breast tissue while avoiding hepatic metabolism and systemic effects, and states the medicament is "intended for the treatment of conditions of the breast, especially benign and even cancerous conditions of the breast." Gynecomastia is, by definition, a benign condition of the breast (the patent's own Background defines it as "the benign and sometimes painful proliferation of breast tissue"). The reference's context is the female breast, but the drug's mechanism (ER blockade in breast tissue) is not sex-specific, and the reference's claim language ("conditions of the breast, especially benign") is broad enough to encompass gynecomastia. At minimum, it provides the "known problem / known solution" predicate.

(b) Gruntmanis & Braunstein 2001 supplies the male-gynecomastia indication (elements 1–2). It teaches that gynecomastia is an estrogen-androgen imbalance at the breast-tissue level and that the ER blocker tamoxifen is the treatment of choice. Since 4-OHT is tamoxifen's active metabolite (Robertson 1982; Jordan 1982; Malet 1988 established greater potency), substituting the active metabolite for the parent drug is a simple substitution of one known element for another with a predictable result (KSR; MPEP 2143). The patent's specification admits this predicate — it cites Gruntmanis & Braunstein for the proposition that "the best treatment results can be expected from the estrogen receptor blockage drug Tamoxifen."

(c) EP 0 513 832 supplies the IPM limitation (element 4) and the motivation. It teaches IPM as a known topical penetration enhancer. Because 4-OHT is a large, lipophilic molecule that "poorly penetrates the skin" (the patent's own characterization), a PHOSITA seeking to deliver it percutaneously would predictably add a known enhancer such as IPM. This is the classic "use of a known technique to improve a similar device in the same way" rationale.

Motivation to combine (why a PHOSITA would do it):

• Tamoxifen's systemic adverse effects (nausea, DVT/PE, cataracts, hepatic toxicity, blood dyscrasias — all recited in the patent's Background) are the recognized problem to be solved; percutaneous delivery was already known to avoid first-pass hepatic metabolism and reduce systemic exposure (US 4,919,937; Mauvais-Jarvis 1986; Pujol 1995).
• US 4,919,937 taught that tamoxifen itself cannot be converted to 4-OHT in the breast (no local enzymes), so the preformed 4-OHT is the logical topical agent.
• The references point to a finite, predictable set of options (topical 4-OHT in an alcohol/gel vehicle with a standard enhancer), satisfying KSR's "obvious to try" rationale.

Result: the only meaningful "gap" is that the prior art's clinical work was in women and used the drug against breast cancer/benign disease rather than specifically against male gynecomastia. That gap is bridged by Gruntmanis & Braunstein and by the patent's own acknowledgment that "male breast tissue, like female breast tissue, can capture 4-hydroxy tamoxifen that has been released through skin," supported by Sasano 1996 (high ER expression in gynecomastia tissue) and Shoker 2000 (Ki67 proliferation).

---

Ground 2 — Mauvais-Jarvis 1986 + Kuttenn 1985 + Gruntmanis & Braunstein 2001 + US 5,613,958

Independent of US 4,919,937:

• Mauvais-Jarvis 1986 is arguably the most on-point reference: it demonstrates percutaneous 4-OHT delivery to human breast tissue and expressly suggests the approach "could be useful in the treatment of hormone-dependent benign breast diseases." Gynecomastia is a hormone-driven benign breast disease. This is a direct teaching of the claimed method's core, absent the sex of the patient.
• Gruntmanis & Braunstein 2001 supplies the male gynecomastia indication and the ER-blockade rationale.
• US 5,613,958 supplies the complete formulation: ethanol (30–70%), IPM (1–5%), hydroxypropylcellulose gelling agent (0.1–10%), water balance — i.e., the vehicle architecture claimed in claims 8–12.

Motivation: combining a known topical anti-estrogen therapy for benign breast disease with the known gynecomastia indication and a known topical vehicle is the assembly of known elements with a predictable result (KSR). The patent offers no evidence that the male-gynecomastia result was unexpectedly different from the female-benign-breast-disease result already reported.

---

Ground 3 — Pujol et al. 1995 + Gruntmanis & Braunstein 2001

Pujol discloses the exact commercial gel later used in the patent's own examples and claimed in dependent claims: the Besins/Iscovesco hydroalcoholic gel at 20 mg 4-OHT per 100 g (i.e., 0.02% w/w — squarely within claim 12's 0.01–0.25% and claim 13's enumerated 0.01–0.10% values), delivered by a metered pump at 0.25 mg/dose, at 0.5, 1, and 2 mg/day, applied directly to both breasts. Combined with Gruntmanis & Braunstein's gynecomastia teaching, this renders the dosing claims (2–7) and the formulation claims (8–13, 20) obvious as routine optimization of known, disclosed parameters.

---

Ground 4 — Dependent claims 12–20 (gel composition ranges) via US 5,613,958 and EP 0 513 832

Every dependent claim maps onto a known formulation element or a disclosed value, and the differences are "mere" optimizations of a disclosed range or selection of a known species — obvious as a matter of law under MPEP 2144.

---

VI. Why the combination is not saved by the "surprising discovery" language

The specification asserts "the surprising discovery that 4-hydroxy tamoxifen, when administered percutaneously, may be effective not only in treating but also in preventing gynecomastia." Under Graham step four, such a statement is a secondary-consideration argument, and it is weak here:

1. No unexpected result. Mauvais-Jarvis 1986 already expressly predicted that percutaneous 4-OHT "could be useful in the treatment of hormone-dependent benign breast diseases." A PHOSITA would have expected an anti-estrogen delivered locally to breast tissue to shrink hormone-driven benign proliferation — the mechanism the patent itself recites. Expectation of success was high, not surprising.
2. Prevention (the other "surprise") is not claimed — claim 1 is a treatment claim; the prophylactic embodiments described in the specification are unclaimed. Secondary considerations must be coextensive with the claimed invention (Pfizer v. Apotex).
3. Teaching away is absent or weak. The only real teaching-away candidate is Pujol's conclusion that "at the doses described in this study, percutaneous 4-OH-TAM cannot be proposed as an alternative tamoxifen treatment." But that conclusion is expressly about matching the breast-tissue concentrations needed for breast-cancer therapy. For gynecomastia, the therapeutic objective is a local anti-estrogenic effect on benign tissue — a different problem. A PHOSITA would not read Pujol's cancer-therapy caveat as discouraging the benign-disease use; indeed, Mauvais-Jarvis 1986 and US 4,919,937 both affirm the benign-disease application. Under In re Gurley, a mere statement of inferiority for a different purpose does not teach away.
4. The claim-1 "isopropyl myristate" limitation cuts against, not for, patentability. The patent's own examples and Table 1 show the IPM-containing gel is the same Besins gel disclosed in Pujol 1995; the advantage obtained (enhanced penetration) is exactly the known property of IPM recited in EP 0 513 832. There is no new, unexpected property attributable to IPM.

---

VII. Conclusion and residual uncertainties

Bottom line. On the record I can see, claim 1 and all dependent claims of US 7,968,532 are vulnerable to a strong § 103 obviousness challenge, primarily:

US 4,919,937 (Mauvais-Jarvis) + Gruntmanis & Braunstein 2001 + EP 0 513 832 (Bristol-Myers Squibb)

with secondary, independent grounds:

Mauvais-Jarvis et al. 1986 + Gruntmanis & Braunstein 2001 + US 5,613,958, and
Pujol et al. 1995 + Gruntmanis & Braunstein 2001 for the dosing and gel-composition claims.

The four claim-1 elements (male gynecomastia patient; percutaneous 4-OHT; effective amount; IPM-containing vehicle) are each taught, and the motivation to combine is supplied both by the recognized defects of oral tamoxifen and by the prior art's express suggestion to use percutaneous 4-OHT for benign breast disease. The patent's "surprising discovery" narrative is undercut by that express suggestion and by the fact that the claim-1 gel is the same prior-art gel.

Uncertainties I want to flag explicitly:

1. I could not retrieve full texts of WO 99/33451 (Hexal) or US 5,613,958 within the tool limits; my characterization of US 5,613,958 rests on a verified quotation from its specification, and of WO 99/33451 on its citation title only. These should be confirmed against the issued documents before being relied upon.
2. US 4,919,937's "male patient" coverage is inferential — the reference's enabling disclosure and clinical data are in women; its claim 4 ("conditions of the breast, especially benign") is what anchors the gynecomastia reading. If a fact-finder required an express male/gynecomastia disclosure, Gruntmanis & Braunstein supplies it, so the combination survives either way.
3. Prosecution history matters. I have not reviewed the applicant's remarks or the examiner's reasons for allowance. The patent apparently issued over cited art including US 4,919,937; the applicant may have argued a specific unexpected result or a teaching-away that is not visible in the face-of-patent record. Any real invalidity contention should be checked against the file wrapper (USPTO PatentCenter) and against whether the examiner considered Gruntmanis & Braunstein in combination with US 4,919,937 and an IPM reference.
4. Secondary considerations (commercial success of the Afimoxifene/4-OHT gel, long-felt need, industry praise) are not evident in the record I retrieved and, in any event, would need a demonstrated nexus to the claimed invention to carry weight. Note the earlier "Litigation summary" found only a license/contract dispute (Atossa Genetics v. Besins Healthcare Luxembourg, D. Del. 1:16-cv-00045-UNA, settled 2016), not an infringement judgment validating the claims — so there is no adjudicated commercial-success finding to rely on.

This analysis is provided for technical assessment purposes and is not legal advice.